Evidence map›Paper›PMID 31638999›Full record

ArticleCell communication and signaling : CCS2019

Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract.

Subhayan Sur, Hiroshi Nakanishi, Colin Flaveny, Joseph E Ippolito, Jane McHowat, David A Ford, Ratna B Ray

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Natural products targeting glycolysis in cancer.Frontiers in pharmacology · 2022
    Pooled it
  3. iScience · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Evaluation of the impact ofHistology and histopathology · 2025
    Article
  9. Nutraceutical Potential of Bitter Melon (Current issues in molecular biology · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Role ofQuantitative biology (Beijing, China) · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Subhayan SurDepartment of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO, 63104, USA.
Hiroshi NakanishiDepartment of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO, 63104, USA.
Colin FlavenyDepartment of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO, USA.
Joseph E IppolitoMallinckrodt Institute of Radiology, Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA.
Jane McHowatDepartment of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO, 63104, USA.
David A FordBiochemistry and Molecular Biology, Saint Louis University, Saint Louis, MO, USA.
Ratna B RayDepartment of Pathology, Saint Louis University, 1100 South Grand Boulevard, St. Louis, MO, 63104, USA. ratna.ray@health.slu.edu.
Saint Louis University · USMallinckrodt (United States) · US

Funding

Mechanistic Insights of BME mediated inhibition of head and neck cancer growthR01DE025141 · NIDCR · SAINT LOUIS UNIVERSITY · PI Ratna B. Ray · 2015 to 2026
$4.2M
NIDCR NIH HHS R01 DE025141
6 · The paper itself

Abstract

backgroundMetabolic reprogramming is one of the hallmarks of cancer which favours rapid energy production, biosynthetic capabilities and therapy resistance. In our previous study, we showed bitter melon extract (BME) prevents carcinogen induced mouse oral cancer. RNA sequence analysis from mouse tongue revealed a significant modulation in "Metabolic Process" by altering glycolysis and lipid metabolic pathways in BME fed group as compared to cancer group. In present study, we evaluated the effect of BME on glycolysis and lipid metabolism pathways in human oral cancer cells.

methodsCal27 and JHU022 cells were treated with BME. RNA and protein expression were analysed for modulation of glycolytic and lipogenesis genes by quantitative real-time PCR, western blot analyses and immunofluorescence. Lactate and pyruvate level was determined by GC/MS. Extracellular acidification and glycolytic rate were measured using the Seahorse XF analyser. Shotgun lipidomics in Cal27 and JHU022 cell lines following BME treatment was performed by ESI/ MS. ROS was measured by FACS.

resultsTreatment with BME on oral cancer cell lines significantly reduced mRNA and protein expression levels of key glycolytic genes SLC2A1 (GLUT-1), PFKP, LDHA, PKM and PDK3. Pyruvate and lactate levels and glycolysis rate were reduced in oral cancer cells following BME treatment. In lipogenesis pathway, we observed a significant reduction of genes involves in fatty acid biogenesis, ACLY, ACC1 and FASN, at the mRNA and protein levels following BME treatment. Further, BME treatment significantly reduced phosphatidylcholine, phosphatidylethanolamine, and plasmenylethanolamine, and reduced iPLA2 activity. Additionally, BME treatment inhibited lipid raft marker flotillin expression and altered its subcellular localization. ER-stress associated CHOP expression and generation of mitochondrial reactive oxygen species were induced by BME, which facilitated apoptosis.

conclusionOur study revealed that bitter melon extract inhibits glycolysis and lipid metabolism and induces ER and oxidative stress-mediated cell death in oral cancer. Thus, BME-mediated metabolic reprogramming of oral cancer cells will have important preventive and therapeutic implications along with conventional therapies.

Indexed as

Antineoplastic AgentsCell Line, TumorGene Expression Regulation, NeoplasticGlycolysisHumansLipogenesisMetabolic Networks and PathwaysMomordica charantiaMouth NeoplasmsPlant ExtractsReactive Oxygen SpeciesTranscription Factor CHOPAntineoplastic AgentsDDIT3 protein, humanPlant ExtractsReactive Oxygen SpeciesTranscription Factor CHOPBitter melon extractGlycolysisLipid metabolismOral cancerPhosphatidylcholinePhosphatidylethanolamineROS

Identifiers

PMID31638999
PMCPMC6802351
OpenAlexW2981844532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.